Library screening identifies commercial drugs as potential structure correctors of abnormal apolipoprotein A-I

• Published in: Journal of lipid research 2024-05, Vol.65 (5), p.100543, Article 100543
• Main Authors: Gkolfinopoulou, Christina, Bourtsala, Angeliki, Georgiadou, Daphne, Dedemadi, Anastasia-Georgia, Stratikos, Efstratios, Chroni, Angeliki
• Format: Article
• Language: English
• Subjects: Animals; apolipoprotein; Apolipoprotein A-I - chemistry; Apolipoprotein A-I - metabolism; atherosclerosis; cholesterol; Drug Evaluation, Preclinical; drug screening; Humans; Mice; protein conformation; small molecule; Small Molecule Libraries - chemistry; Small Molecule Libraries - pharmacology
• ISSN: 0022-2275; 1539-7262; 1539-7262
• DOI: 10.1016/j.jlr.2024.100543

AapoA-I, the main protein of high-density lipoprotein, plays a key role in the biogenesis and atheroprotective properties of high-density lipoprotein. We showed previously that a naturally occurring apoA-I mutation, L178P, induces major defects in protein’s structural integrity and functions that may underlie the increased cardiovascular risk observed in carriers of the mutation. Here, a library of marketed drugs (956 compounds) was screened against apoA-I[L178P] to identify molecules that can stabilize the normal conformation of apoA-I. Screening was performed by the thermal shift assay in the presence of fluorescent dye SYPRO Orange. As an orthogonal assay, we monitored the change in fluorescence intensity of 8-anilinonaphthalene-1-sulfonic acid upon binding on hydrophobic sites on apoA-I. Screening identified four potential structure correctors. Subsequent analysis of the concentration-dependent effect of these compounds on secondary structure and thermodynamic stability of WT apoA-I and apoA-I[L178P] (assessed by thermal shift assay and circular dichroism spectroscopy), as well as on macrophage viability, narrowed the potential structure correctors to two, the drugs atorvastatin and bexarotene. Functional analysis showed that these two compounds can restore the defective capacity of apoA-I[L178P] to promote cholesterol removal from macrophages, an important step for atheroprotection. Computational docking suggested that both drugs target a positively charged cavity in apoA-I, formed between helix 1/2 and helix 5, and make extensive interactions that could underlie thermodynamic stabilization. Overall, our findings indicate that small molecules can correct defective apoA-I structure and function and may lead to novel therapeutic approaches for apoA-I–related dyslipidemias and increased cardiovascular risk. [Display omitted]